Effects of Xuezhikang Capsule(血脂康胶囊) on Blood Lipids,Platelet Activation and Coagulation-Fibrinolysis Activity in Patients with Hyperlipidemia

Objective: To investigate the effects of Xuezhikang capsule (XZK,血脂康胶囊) on blood lipids level, platelet activation and coagulation-fibrinolysis activity in patients with hyerlipidemia. Methods: Seventy-six patients of hyperlipidemia were randomly divided into two groups, the XZK group (n=38) treated with XZK 600mg, taken two times per day and the Simvastatin (SIM) group (n = 38) treated with SIM 20mg per day, with the treatment lasting 8 weeks for both groups. Levels of fasting serum lipids, including total cholesterol (TC), triglyceride (TG), high and low density lipoprotein cholesterol (HDL-C and LDL-C), plasma GMP-140, fibrinogen (FIB), tissue plasminogen activator (t-PA), plasminogen activator inhibitor type-1 (PAI-) and prothrombin time (PT) were all measured before and 8 weeks after treatment. Data were compared before and after treatment and also compared with those measured in 20 healthy subjects of control. Results: Before treantment the levels of TC, TG and LDL-C were obviously higher and HDL-C level was significantly lower in hyperlipidemia patients than those in healthy subjects (P<0.05 or P<0.01). After 4-8 weeks of XZK treatment, the levels of TC, TG, LDL-C and FIB and activities of GMP-140 and PAI-1 were obviously lowered (P<0. 05 or P<0. 01). But in the SIM group there was no obvious change in FIB (P>0.05), instead it showed obvious increase of HDL-C and decrease of TC and LDL-C after treatment (P<0.05 or P<0.01). Conclusion: XZK could inhibit platelet activity and improve coagulation-fibrinolysis function, besides its lipids lowering effect.

Effect of Xuezhikang Capsule(血脂康胶囊)on Serum Tumor Necrosis Factor-αand Interleukin-6 in Patients with Nonalcoholic Fatty Liver Disease and Hyperlipidemia

Objective：To evaluate the effect of Xuezhikang Capsule（血脂康胶囊） on the serum levels of inflammatory factors such as tumor necrosis factor-α（TNF-α） and interleukin-6（IL-6） in patients with nonalcoholic fatty liver disease（NAFLD） and hyperlipidemia,and to explore whether it has anti-inflammatory effect.Methods：A total of 84 patients were randomly assigned to two groups with stratified block randomization, the treatment group（42 cases） and the control group（42 cases）.They were treated with Xuezhikang Capsule and polyene phosphatidylcholine capsule for twenty-four weeks,respectively.The changes in serum TNF-αand IL-6 were measured by enzyme linked immunosorbent assay before treatment and at the 12th and 24th week. Results：Compared with those before treatment,the serum levels of TNF-αand IL-6 significantly decreased in both groups after treatment（P〈0.01）.There was no significant change between the two groups for the treatments at different time points（P〉0.05） and between the two groups for treatments at the same time points （P〉0.05）.Conclusion：Xuezhikang Capsule can inhibit the serum inflammatory factor in patients with NAFLD and hyperlipidemia.

Effects of Combined Therapy of Xuezhikang Capsule(血脂康胶囊)and Valsartan on Hypertensive Left Ventricular Hypertrophy and Heart Rate Turbulence

Objective：To observe the effect of combined therapy with Xuezhikang Capsule（血脂康胶囊,XZK） and Valsartan on left ventricular hypertrophy（LVH） and heart rate turbulence（HRT） in hypertensive patients. Methods：Ninety primary hypertensive patients with LVH were randomly assigned to three groups.Basic treatment,including aspirin,β-blockers,calcium antagonists,etc.were administered to all patients.Additionally, Valsartan（VS,80 mg once a day） was given to the 30 patients in the VS group.Valsartan（in the same dosage） and XZK（600 mg,twice a day） were given to the 32 patients in the Chinese medicine（CM） group,while none was given to the 28 patients in the control group.The therapeutic course lasted for 24 months.Changes in left ventricular mass index（LVMI） measured by cardiac ultrasonic indices,HRT parameters,including the original heart rate（TO） and slope coefficient（TS）,systolic and diastolic blood pressures（SBP and DBP）,as well as blood cholesterol level（TC） were measured before and after treatment.Results：After treatment,TO and LVMI were lowered,while TS increased in both the VS group and the CM group（P〈0.01）,but changed insignificantly in the control group.Significant differences between the CM group and the control group were shown in terms of TO,LVMI,SBP,DBP and TS（P〈0.01）;and between the CM group and the VS group in terms of TO,LVMI and TS（P〈0.01）.Moreover,HRT parameters showed an evident correlation with LVMI（r=0.519-0.635,P〈0.01）. Conclusion：Combined therapy with XZK and Valsartan can improve hypertensive LVH and HRT parameters, and lessen the damage on the autonomous nervous system.

Protective effect of Xuezhikang capsules in rats with acute myocardial ischemia reperfusion injury

Background Recent researches have found that stains can improve acute myocardial ischemia reperfusion injury which is achieved by inhibiting inflammatory reaction.Xuezhikang is extracted from red rice,a tailor-made Chinese crude drug.Main component of Xuezhikang that can inhibit blood-fat is statins.Methods Forty healthy SD rats （half male and half female,200 g or so） were randomly divided into four groups：A：normal control;B：sham operation;C：MIR group;D：Xuezhikang group.The acute myocardial ischemia reperfusion injury model was produced.Infarct sizes,MYO,CK-MB,cTnI,IL-10 and IL-18 were detected after reperfusion.Results Compared with C and D group,in A and B group,infarct size were increased significantly （P 0.01）,the level of serum MYO,CK-MB,cTnI were increased significantly （P 0.01）,the level of IL-10 were decreased significantly （P 0.01） and IL-18,CRP were increased significantly （P 0.01）.Compared with C group,infarct size were decreased significantly （P 0.05）,the level of serum MYO,CK-MB and cTnI were increased significantly（P 0.05）,the level of IL-10 were increased significantly （P 0.05） and IL-18 were decreased significantly （P 0.05）.The level of IL-10 and IL-18 were no difference between A and B group.Conclusion The application of Xuezhikang capsules on rats before the operation of myocardial ischemia reperfusion can lessen inflammatory reaction and reduce infarct sizes and protect acute myocardial ischemia reperfusion.